Evidence map›Paper›PMID 38128551›Full record

ArticleBrain : a journal of neurology2024

Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer's disease.

Nicola Spotorno, Olof Strandberg, Erik Stomrud, Shorena Janelidze, Kaj Blennow, Markus Nilsson, Danielle van Westen, Oskar Hansson

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Hippocampal grey matter changes across scales in Alzheimer's Disease.bioRxiv : the preprint server for biology · 2025
    Article
  17. Article
  18. Sex differences in vulnerability to tau pathology: Impact on cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nicola SpotornoClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, 223 62 Lund, Sweden.ORCID 0000-0001-5404-8788
Olof StrandbergClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, 223 62 Lund, Sweden.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, 223 62 Lund, Sweden.
Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, 223 62 Lund, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
Markus NilssonDiagnostic Radiology, Institution for Clinical Sciences, Lund University, 221 85 Lund, Sweden.
Danielle van WestenClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, 223 62 Lund, Sweden.ORCID 0000-0001-8649-9874
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, 223 62 Lund, Sweden.ORCID 0000-0001-8467-7286
Lund University · SESahlgrenska University Hospital · SE

Funding

Cure Alzheimer's fundERA PerMed ERAPERMED2021-184Knut and Alice Wallenberg foundation 2017-0383Konung Gustaf V:s och Drottning Victorias FrimurarestiftelseLund UniversityRegionalt Forskningsstöd 2022-1259Skåne University Hospital Foundation 2020-O000028Swedish Alzheimer Foundation AF-980907Swedish Brain Foundation FO2021-0293Swedish Research Council 2022-00775
6 · The paper itself

Abstract

There is increased interest in developing markers reflecting microstructural changes that could serve as outcome measures in clinical trials. This is especially important after unexpected results in trials evaluating disease-modifying therapies targeting amyloid-β (Aβ), where morphological metrics from MRI showed increased volume loss despite promising clinical treatment effects. In this study, changes over time in cortical mean diffusivity, derived using diffusion tensor imaging, were investigated in a large cohort (n = 424) of non-demented participants from the Swedish BioFINDER study. Participants were stratified following the Aβ/tau (AT) framework. The results revealed a widespread increase in mean diffusivity over time, including both temporal and parietal cortical regions, in Aβ-positive but still tau-negative individuals. These increases were steeper in Aβ-positive and tau-positive individuals and robust to the inclusion of cortical thickness in the model. A steeper increase in mean diffusivity was also associated with both changes over time in fluid markers reflecting astrocytic activity (i.e. plasma level of glial fibrillary acidic protein and CSF levels of YKL-40) and worsening of cognitive performance (all P < 0.01). By tracking cortical microstructural changes over time and possibly reflecting variations related to the astrocytic response, cortical mean diffusivity emerges as a promising marker for tracking treatments-induced microstructural changes in clinical trials.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesDiffusion Magnetic Resonance ImagingDiffusion Tensor ImagingHumansIntermediate FilamentsAmyloid beta-PeptidesAlzheimer’s diseaseamyloid-βastrocytesclinical trialscortical mean diffusivity

Identifiers

PMID38128551
PMCPMC10907088
OpenAlexW4390120486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.